UNASSIGNED: Previous work demonstrated that serum metabolomics can distinguish @entity788 from benign disease. However, in the clinic, @entity788 are difficult to distinguish from @entity788 . Therefore, to test the clinical utility of this technology, we determined whether any @entity788 could be distinguished from benign masses and @entity253 . Sera from 157 @entity1 with @entity660 were analyzed using proton nuclear magnetic resonance (  @entity8108 -NMR) spectroscopy and gas chromatography-mass spectrometry (GC-MS). Multivariate projection modeling using SIMCA-P+ software in training datasets (n = 80) was used to generate the best models to differentiate disease states. Models were validated in test datasets (n = 77). The final   @entity8108 -NMR spectroscopy and GC-MS metabolomic profiles consisted of 14 and 18 compounds, with AUROC values of 0.74 (SE 0.06) and 0.62 (SE 0.08), respectively. The combination of   @entity8108 -NMR spectroscopy and GC-MS metabolites did not substantially improve this performance (AUROC 0.66, SE 0.08). In @entity1 with @entity420 , @entity3264 levels were consistently higher, while @entity3264 and @entity3929 levels were consistently lower. @entity788 can be distinguished from benign lesions. To further enhance the discriminatory power of metabolomics in this setting, it will be important to identify the metabolomic changes that characterize each of the subclasses of this heterogeneous group of @entity5 .

Distinguishing Benign from Malignant Pancreatic and Periampullary Lesions Using Combined Use of   XXXX -NMR Spectroscopy and Gas Chromatography-Mass Spectrometry.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatic and periampullary adenocarcinoma', 'Pancreatic and periampullary adenocarcinomas', 'non-pancreatic periampullary cancers', 'pancreatic cancer'] @entity3264 :: ('D018698', 'Chemical') :: ['glutamine', 'glutamate'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancers'] @entity660 :: ('MESH:D010182', 'Disease') :: ['malignant and benign pancreatic and periampullary lesions'] @entity3929 :: ('D000409', 'Chemical') :: ['alanine'] @entity8108 :: ('D006859', 'Chemical') :: ['H'] @entity253 :: ('MESH:D001660', 'Disease') :: ['biliary strictures'] @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma']
@entity8108 :: (D006859,Chemical) :: ['H']
